
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biot...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

Ep. 115 - Initiate's Owens on what it takes to be AI-native
Free AI-powered recaps of The BioCentury Show and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.